drugset
drugset / Trial / NCT04577703

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

NCT04577703 ↗

Phase 1 Completed 20 enrolled Sunshine Lake Pharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I, single-arm, single-center, open-label, dose-escalation Study evaluating the safety and efficacy of CT053PTSA in patients with Advanced Solid Tumors

Timeline

Start
2014-02-08
Primary completion
2015-12-10
Completion
2015-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CT053PTSA Unknown 15 mg Oral
Subject CT053PTSA Unknown 30 mg Oral
Subject CT053PTSA Unknown 60 mg Oral
Subject CT053PTSA Unknown 100 mg Oral
Subject CT053PTSA Unknown 150 mg Oral

Indications

neoplasm